On July 29, 2026, in Irvine, California, Beta Bionics, Inc. (Nasdaq: BBNX), a company focused on innovative diabetes management solutions, shared its financial performance for the quarter concluding on June 30, 2026. The company also revised its annual guidance for the year ending on December 31, 2026.